Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2002

View Archived Issues

Research snapshots in sexual dysfunction

Schering-Plough reports Clarinex launch imminent

Third Wave and Daiichi to develop diagnostic products for use with irinotecan

FDA approves Uni-Gold Strep A rapid test

Sweden expands approved use of Viragen's natural interferon alfa

MorphiDex patient enrollment progressing behind schedule

Mechanism and potential treatments for learning disability in NF1 patients identified

Pharmacia's broad R&D pipeline includes two potential blockbusters

Mechanism of analgesic effect of Esterom identified by Brigham & Women's team

Large, long-term study in Australia seeking optimal HIV treatment strategy

Beneficial effects reported for antisense inhibition of MIP-1alpha in multiple myeloma

Vivus cleared to proceed with TA-1790 trial in erectile dysfunction

Patient treatment commences in phase II trial of RSD-1235 in atrial fibrillation

Arius postpones murine ARH460-23 antibody development

DMXAA in combination with chemotherapy produces positive results in mice

Preparations under way for trial of Ampakine in mild cognitive impairment

Therapeutic potential of IL-18 neutralization examined in mouse model of arthritis

P&G assumes marketing of Asacol in the U.K.

Phenyl-substituted heterocyclic ketones with selective COX-2-inhibitory activity

Aventis synthesizes urea and thiourea derivatives as inhibitors of factor VIIa

Melanocortin receptor agonists and uses thereof claimed by Merck

New GSK compounds useful for treatment and prophylaxis of sCD23-mediated conditions

Takeda presents new inhibitors of tyrosine phosphatases

Ligands for the benzodiazepine site on GABA-A receptors in the Neurogen pipeline

New metabolically stable gabapentin analogues described in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...